ANT 005 TKA Trial: Abelacimab for VTE

ant tka trial abelacimab vte
 2021 ANT-005 TKA TRIAL M Abelacimab for Prevention of Venous Thromboembolism (VTE) Phase 2,open-label, prospective randomized trial 400 Objective: To compare the efficacy & safety of abelacimab administered postoperatively with the efficacy & safety of enoxaparin in patients undergoing total knee arthroplasty. patients Inclusion criteria: Patients 18 to 80 years of age undergoing elective primary unilateral total knee arthroplasty & those with active bleeding or a high risk of bleeding or h/o VTE were ruled out. (A)Abelacimab 30 mg [n = 102] 13 2 (A)Abelacimab (A)Abelacimab (E)Enoxaparin 75 mg [n = 99] 150 mg [n = 98] 40mg [n = 101] PRIMARY OUTCOME Incidence of venous thromboembolism % (A)30mg vs (E) :Diff -9.2; P=0.08 (A)75mg vs (E) :Diff -16.8; P< 0.001 (A)150mg vs (E) :Diff -17.8; P< 0.001 All 3 regimens of Abelacimab met noninferiority criteria 5 4 SECONDARY OUTCOME Major or clinically relevant non major bleeding within 30 days% 2 22 Conclusion: A single intravenous dose of abelacimab after total knee arthroplasty was effective for the prevention of venous thromboembolism and was associated with a low risk of bleeding P Verhamme et al. NEJM 2021; 385:609-617


Comments are closed.